NeurologyLive® Friday 5 — June 28, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Amyloid and Non-Amyloid Advanced Therapeutics in Dementia: R. Scott Turner, PhD, MD, FANA, FAAN

The director of the Memory Disorders Program at Georgetown University talked about newly approved anti-amyloid antibodies that show significant promise in slowing Alzheimer disease progression. [WATCH TIME: 5 minutes]

2: Disease-Modifying Therapies for Dementia in Movement Disorders: Charbel Moussa, MBBS, PhD

The associate professor of neurology at Georgetown University Medical Center talked about disease-modifying therapies for movement disorder-related dementia that aim to address the underlying mechanisms of the disease. [WATCH TIME: 5 minutes]

3: Overcoming Barriers in Communication for Patient Disclosure in Movement Disorders: Kelly Papesh, DNP, APRN, FNP-BC

The executive director of the Association of Movement Disorder Advanced Practice Providers talked about the need for improved communication and trust of the patient-provider relationship in the field of movement disorders. [WATCH TIME: 3 minutes]

4: NeuroVoices: Sanjay R. Patel, MD, MS, on Advances in Pharmaceutical Treatment for Sleep Apnea

In this week's NeuroVocies Q&A, the director of the Center for Sleep and Cardiovascular Outcomes Research at University of Pittsburgh talked about a phase 3 trial assessing a pharmaceutical treatment, AD109, in sleep apnea.

5: Limitations and Promise of Synuclein Biomarkers in Parkinson Disease Diagnosis: David Shprecher, DO, MSci, FAAN

The director of movement disorders at the Banner Sun Health Research Institute talked about that although synuclein biomarkers have shown high sensitivity in identifying Parkinson disease, further studies are needed to address their limitations. [WATCH TIME: 3 minutes]